ArticleProceedings of the National Academy of Sciences of the United States of America2018
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Metabolic-epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment.Experimental & molecular medicine · 2026Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications.Discover oncology · 2025Review
- Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer.Cellular & molecular biology letters · 2025Review
- Hypoxia alters the response of ovarian cancer cells to the mitomycin C drug.Frontiers in cell and developmental biology · 2025Article
- The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer.Frontiers in oncology · 2022Review
- [Effects of lentivirus-mediated RNA interference of HIF-1α and PTEN on oxygen-glucose deprivation injury in primary cultured rat neurons].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- RETRACTED: Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular abnormalization to promote tumor budding.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons.Journal of experimental & clinical cancer research : CR · 2021Review
- HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer.The Journal of clinical investigation · 2020Review
- Autonomous glucose metabolic reprogramming of tumour cells under hypoxia: opportunities for targeted therapy.Journal of experimental & clinical cancer research : CR · 2020Review
- Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.Journal of experimental & clinical cancer research : CR · 2020Review
- The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.Cancer research · 2020Article
- Targeting mRNA processing as an anticancer strategy.Nature reviews. Drug discovery · 2020Review
- DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment.Frontiers in genetics · 2020Review
- β‑elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A‑VEGFA pathway based on network pharmacology.Oncology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Andrew G LiDepartment of Genetics, Harvard Medical School, Boston, MA 02115; andrew_li@dfci.harvard.edu david_livingston@dfci.harvard.edu.
Elizabeth C MurphyDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Aedin C CulhaneDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Emily PowellDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Hua WangDepartment of Genetics, Harvard Medical School, Boston, MA 02115.
Roderick T BronsonDepartment of Pathology, Harvard Medical School, Boston, MA 02115.
Thanh VonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Anita Giobbie-HurderDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Rebecca S GelmanDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Kimberly J BriggsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Helen Piwnica-WormsDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Jean J ZhaoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Andrew L KungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
William G KaelinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
David M LivingstonDepartment of Genetics, Harvard Medical School, Boston, MA 02115; andrew_li@dfci.harvard.edu david_livingston@dfci.harvard.edu.
Dana-Farber Cancer Institute · USHarvard University · USThe University of Texas MD Anderson Cancer Center · USHoward Hughes Medical Institute · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MUse of Organotypic and Mammary Gland Models to Investigate the Outcomes of ClonalP01CA080111 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI DILLON, DEBORAH · 1999 to 2018
$36.0MIntegrating targeted therapy and immunotherapy to break through cancerR35CA210057 · NCI · DANA-FARBER CANCER INST · PI Jean Zhao · 2016 to 2026
$10.8MThe von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8MNCI NIH HHS P01 CA080111NCI NIH HHS P30 CA006516NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA101942NCI NIH HHS R35 CA210057NCI NIH HHS R35 CA210068
Abstract
PubMed holds no abstract for this paper.
Indexed as
Alternative SplicingSignal TransductionAnimalsBRCA1 ProteinHumansHypoxia-Inducible Factor 1, alpha SubunitMiceNeoplasmsPTEN PhosphohydrolaseBRCA1 ProteinBRCA1 protein, humanHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitPTEN PhosphohydrolasePTEN protein, humanBRCA1-IRISHIF-1αmetastasisPTEN
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.